financetom
Business
financetom
/
Business
/
Franklin Templeton's quarterly profit dips as outflow cuts into investment management fees
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Franklin Templeton's quarterly profit dips as outflow cuts into investment management fees
Aug 1, 2025 7:38 AM

Aug 1 (Reuters) - Investment manager Franklin Resources ( BEN )

, better known as Franklin Templeton, reported a fall in

third-quarter profit on Friday, as client outflow cut into its

investment management fees, sending its shares down 6% in early

trading.

Investors have been pulling out funds from Franklin

subsidiary Western Asset Management after a federal

investigation charged Kenneth Leech, the unit's former co-chief

investment officer, with running a "cherry-picking" scheme.

Leech was charged with fraudulently favoring some clients'

accounts over others when allocating trades.

The asset manager's total long-term net outflows were $9.3

billion during the third quarter. Excluding Western Asset

Management, its long-term net inflows were $7.8 billion.

Franklin's total investment management fees, the largest

contributor to its total operating revenue, fell 3% to $1.64

billion during the quarter.

U.S. President Donald Trump's erratic trade policies have

unsettled the market, leaving investors waiting for greater

clarity regarding the economic environment.

As a result, investors have increasingly shifted toward

safer assets such as U.S. Treasury bonds and gold, pulling back

from equities, which are a riskier bet to make at a time when

the markets are volatile.

Franklin Templeton ended the quarter with $1.61 trillion in

assets under management, down 2% from a year ago.

Excluding one-time costs, Franklin's quarterly profit was

$263.4 million, or 49 cents per share, compared with an average

of $326.4 million, or 60 cents, a year ago.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Foresight Autonomous Signs Cooperation Deal With Excava in India
Foresight Autonomous Signs Cooperation Deal With Excava in India
Mar 13, 2025
08:46 AM EDT, 03/13/2025 (MT Newswires) -- Foresight Autonomous ( FRSX ) said Thursday it signed a commercial cooperation agreement with Indian automotive supplier Excava Attachers to promote its 3D perception systems in India. Financial terms were not provided. Under the agreement, Excava will handle manufacturing and sales, while Foresight will provide technology and know-how, the company said, adding that...
Why Is G-III Apparel Stock Shooting Higher Today?
Why Is G-III Apparel Stock Shooting Higher Today?
Mar 13, 2025
G-III Apparel Group Ltd ( GIII ) shares are trading higher in premarket on Thursday after the fourth-quarter FY25 earnings report. The company reported fourth-quarter sales growth of 9.8% year-on-year to $839.535 million, beating the analyst consensus estimate of $807.590 million. The gross profit rose 17.6% Y/Y to $331.6 million, with the margin expanding 270 basis points to 39.5%. Selling,...
BRIEF-Wang & Lee Group, Inc. Announces Acquisition Of Solar (Hk) Limited, Paving The Way For Global Renewable Crypto Mining
BRIEF-Wang & Lee Group, Inc. Announces Acquisition Of Solar (Hk) Limited, Paving The Way For Global Renewable Crypto Mining
Mar 13, 2025
March 13 (Reuters) - WANG & LEE GROUP Inc ( WLGS ): * WANG & LEE GROUP, INC. ( WLGS ) ANNOUNCES ACQUISITION OF SOLAR (HK) LIMITED, PAVING THE WAY FOR GLOBAL RENEWABLE CRYPTO MINING * WANG & LEE GROUP INC ( WLGS ) - TO ACQUIRE SOLARHK FOR HK$15 MILLION Source text: Further company coverage: ...
Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice
Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice
Mar 13, 2025
08:41 AM EDT, 03/13/2025 (MT Newswires) -- Tempest Therapeutics ( TPST ) said Thursday that the mid-stage clinical trial of TPST-1495 for the treatment of familial adenomatous polyposis has received a study may proceed letter from the US Food and Drug Administration. The clinical-stage company said the Cancer Prevention Clinical Trials Network will run the mid-stage study, which will start...
Copyright 2023-2026 - www.financetom.com All Rights Reserved